DYAI: Dapibus on the Menu
By John Vandermosten, CFA
NASDAQ:DYAI
READ THE FULL DYAI RESEARCH REPORT
Benzinga ·
Get all your news in one place.
100's of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100's of premium titles. One news app.
The Latest Breaking News from DYAI
Recap: Dyadic International Q1 Earnings
Dyadic International (NASDAQ:DYAI) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Benzinga ·
India Funds Affordable COVID-19 Vaccine Candidate Using Dyadic's Platform
Dyadic International Inc's (NASDAQ:DYAI) licensee, Epygen Biotech PVD, LTD., has received funding from the Government of India to advance an affordable COVID-19 vaccine candidate through Phase 1 and Phase 2 trials. Epygen's COVID-19 vaccine utilizes Dyadic's C1 protein production platform. Epygen Biotech is an Indian Biopharmaceutical company engaged in research and manufacturing therapeutic proteins…
Benzinga ·
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Read news from The Economist, FT, and more,
with one subscription
with one subscription
Coverage From
Benzinga
People
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Organisations
Read news from The Economist, FT, and more,
with one subscription
with one subscription
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.
100+ trusted global sources.
